Edwards Lifesciences (EW) Tops Q4 EPS by 11c, FY15 EPS Guidance Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Edwards Lifesciences (EW) Estimates Raised at Jefferies Following 'Stellar' Q4
February 4, 2015 8:43 AM ESTJefferies analyst Raj Denhoy reiterated a Buy rating and $155 price target on Edwards Lifesciences (NYSE: EW) while raising estimates following strong q4 results.
Denhoy commented, "EW posted a stellar 4Q, highlighted by (1) robust TAVR performance across geographies, particularly EU, despite increasing competitionand the... More
